​

Doximity (DOCS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DOCS Stock Forecast

Doximity stock forecast is as follows: an average price target of $53.00 (represents a -8.10% downside from DOCS’s last price of $57.67) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

DOCS Price Target

The average price target for Doximity (DOCS) is $53.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $43.00. This represents a potential -8.10% downside from DOCS's last price of $57.67.

DOCS Analyst Ratings

Buy

According to 10 Wall Street analysts, Doximity's rating consensus is 'Buy'. The analyst rating breakdown for DOCS stock is 0 'Strong Buy' (0.00%), 6 'Buy' (60.00%), 4 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Doximity Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 13, 2025Stan BerenshteynWells Fargo$43.00$55.48-22.49%-25.44%
Jan 08, 2025Scott SchoenhausKeyBanc$65.00$55.4817.16%12.71%
Nov 14, 2024Jailendra SinghTruist Financial$49.00$52.60-6.84%-15.03%
Nov 13, 2024Richard CloseCanaccord Genuity$60.00$35.6068.54%4.04%
Nov 08, 2024Scott BergNeedham$65.00$57.6012.85%12.71%
Nov 08, 2024Stan BerenshteynWells Fargo$41.00$42.09-2.59%-28.91%
Nov 08, 2024Scott SchoenhausKeyBanc$70.00$43.4261.22%21.38%
Oct 15, 2024Stephanie DavisBarclays$52.00$41.9623.93%-9.83%
Oct 08, 2024Elizabeth AndersonEvercore ISI$45.00$43.224.12%-21.97%
Oct 07, 2024Allen LutzBank of America Securities$45.00$43.832.67%-21.97%
Aug 09, 2024Scott BergNeedham$38.00$25.6648.09%-34.11%
May 17, 2024Stephanie DavisBarclays$31.00$27.8911.15%-46.25%
May 17, 2024Jailendra SinghTruist Financial$31.00$23.7430.58%-46.25%
May 17, 2024Elizabeth AndersonEvercore ISI$29.00$23.7422.16%-49.71%
Apr 23, 2024Craig HettenbachMorgan Stanley$25.00$25.01-0.04%-56.65%
Apr 01, 2024Elizabeth AndersonEvercore ISI$30.00$26.4113.59%-47.98%
Oct 23, 2022Elizabeth AndersonEvercore ISI$28.00$25.0211.91%-51.45%
Aug 05, 2022Jessica TassanPiper Sandler$39.00$40.31-3.25%-32.37%

The latest Doximity stock forecast, released on Jan 13, 2025 by Stan Berenshteyn from Wells Fargo, set a price target of $43.00, which represents a -22.49% decrease from the stock price at the time of the forecast ($55.48), and a -25.44% decrease from DOCS last price ($57.67).

Doximity Price Target by Period

1M3M12M
# Anlaysts2716
Avg Price Target$54.00$56.14$44.94
Last Closing Price$57.67$57.67$57.67
Upside/Downside-6.36%-2.65%-22.07%

In the current month, the average price target of Doximity stock is $54.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a -6.36% decrease as opposed to Doximity's last price of $57.67. This month's average price target is down -3.81% compared to last quarter, and up 20.16% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025KeyBancOverweightOverweightHold
Nov 14, 2024Morgan StanleyUnderweightEqual-WeightUpgrade
Nov 13, 2024Canaccord GenuityHoldDowngrade
Nov 08, 2024Bank of America SecuritiesNeutralNeutralHold
Nov 08, 2024KeyBancOverweightUpgrade
Oct 15, 2024BarclaysEqual-WeightOverweightUpgrade
Oct 08, 2024Evercore ISIOutperformOutperformHold
Aug 20, 2024JefferiesBuyBuyHold
Aug 09, 2024Morgan StanleyUnderweightUnderweightHold
Aug 09, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 18, 2024Evercore ISIUnderperformUnderperformHold
Jul 18, 2024Wells FargoNeutralNeutralHold
Jul 18, 2024Wells FargoMarket PerformUnderweightDowngrade
May 17, 2024Evercore ISIPerformPerformHold
Apr 23, 2024Wells FargoMarket PerformMarket PerformHold
Apr 02, 2024Wells FargoMarket PerformMarket PerformHold
Apr 02, 2024Leerink PartnersUnderperformUnderperformHold
Feb 09, 2024Wells FargoEqual-WeightEqual-WeightHold
May 18, 2022NeedhamBuyBuyHold
May 18, 2022JefferiesBuyBuyHold
May 18, 2022Morgan StanleyEqual-WeightEqual-WeightHold
May 18, 2022SVB LeerinkOutperformOutperformHold

Doximity's last stock rating was published by KeyBanc on Jan 08, 2025. The company gave DOCS a "Overweight" rating, the same as its previous rate.

Doximity Financial Forecast

Doximity Revenue Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Revenue-------------$135.28M$113.61M$108.47M$110.97M$115.26M$102.19M$90.64M$93.65M$97.88M$79.35M$72.67M
Avg Forecast$148.02M$181.68M$163.45M$149.92M$136.83M$168.38M$149.78M$138.60M$123.83M$152.82M$127.13M$119.88M$116.41M$127.50M$109.05M$107.00M$110.09M$111.28M$100.15M$89.61M$90.14M$86.26M$73.49M$63.62M
High Forecast$158.33M$194.33M$174.83M$160.36M$146.36M$180.10M$160.21M$148.25M$129.15M$153.28M$127.58M$119.88M$116.41M$128.11M$109.66M$114.45M$117.75M$116.90M$100.15M$89.61M$90.14M$86.26M$73.49M$63.62M
Low Forecast$144.90M$177.84M$160.00M$146.75M$133.94M$164.82M$146.62M$135.67M$121.26M$152.28M$126.68M$119.88M$116.41M$127.10M$108.56M$104.74M$107.76M$109.63M$100.15M$89.61M$90.14M$86.26M$73.49M$63.62M
# Analysts6661211109813126548136655511121110
Surprise %-------------1.06%1.04%1.01%1.01%1.04%1.02%1.01%1.04%1.13%1.08%1.14%

Doximity's average Quarter revenue forecast for Mar 24 based on 4 analysts is $116.41M, with a low forecast of $116.41M, and a high forecast of $116.41M. DOCS's average Quarter revenue forecast represents a -13.95% decrease compared to the company's last Quarter revenue of $135.28M (Dec 23).

Doximity EBITDA Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts6661211109813126548136655511121110
EBITDA-------------$58.55M$33.79M$32.29M$35.55M$41.10M$34.69M$24.05M$29.29M$37.17M$26.53M$26.07M
Avg Forecast$45.82M$56.24M$50.60M$46.41M$42.36M$52.12M$46.37M$42.91M$38.34M$47.31M$39.36M$37.11M$21.25M$39.47M$33.76M$33.12M$19.32M$26.99M$30.55M$27.33M$17.56M$26.31M$22.41M$24.05M
High Forecast$49.01M$60.16M$54.12M$49.64M$45.31M$55.75M$49.60M$45.89M$39.98M$47.45M$39.50M$37.11M$25.50M$39.66M$33.95M$35.43M$23.18M$32.38M$30.55M$27.33M$21.08M$26.31M$22.41M$28.86M
Low Forecast$44.86M$55.05M$49.53M$45.43M$41.46M$51.02M$45.39M$42.00M$37.54M$47.14M$39.22M$37.11M$17.00M$39.34M$33.61M$32.42M$15.46M$21.59M$30.55M$27.33M$14.05M$26.31M$22.41M$19.24M
Surprise %-------------1.48%1.00%0.97%1.84%1.52%1.14%0.88%1.67%1.41%1.18%1.08%

4 analysts predict DOCS's average Quarter EBITDA for Mar 24 to be $21.25M, with a high of $25.50M and a low of $17.00M. This is -63.70% lower than Doximity's previous annual EBITDA (Dec 23) of $58.55M.

Doximity Net Income Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts6661211109813126548136655511121110
Net Income-------------$47.96M$30.60M$28.41M$30.67M$33.47M$26.30M$22.38M$36.73M$55.65M$36.09M$26.32M
Avg Forecast----$55.11M$73.52M$63.98M$58.58M$46.14M$67.62M$51.12M$44.73M$26.66M$47.76M$33.61M$28.64M$24.24M$40.40M$29.99M$19.95M$22.04M$22.21M$17.34M$24.28M
High Forecast----$60.10M$80.17M$69.77M$63.88M$56.62M$71.72M$51.33M$44.74M$32.00M$49.75M$37.34M$31.23M$29.09M$48.48M$29.99M$19.95M$26.44M$22.21M$17.34M$29.14M
Low Forecast----$53.60M$71.50M$62.23M$56.97M$44.04M$65.57M$50.91M$44.71M$21.33M$43.78M$29.88M$27.85M$19.39M$32.32M$29.99M$19.95M$17.63M$22.21M$17.34M$19.43M
Surprise %-------------1.00%0.91%0.99%1.27%0.83%0.88%1.12%1.67%2.51%2.08%1.08%

Doximity's average Quarter net income forecast for Mar 24 is $26.66M, with a range of $21.33M to $32.00M. DOCS's average Quarter net income forecast represents a -44.40% decrease compared to the company's last Quarter net income of $47.96M (Dec 23).

Doximity SG&A Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts6661211109813126548136655511121110
SG&A-------------$44.60M$39.17M$43.70M$42.91M$42.73M$37.77M$36.86M$36.54M$34.78M$29.99M$26.57M
Avg Forecast$56.15M$68.92M$62.00M$56.87M$51.90M$63.87M$56.82M$52.58M$46.97M$57.97M$48.23M$45.48M$26.53M$48.36M$41.37M$40.59M$24.12M$25.25M$37.99M$33.99M$21.93M$32.72M$27.88M$24.51M
High Forecast$60.06M$73.72M$66.32M$60.83M$55.52M$68.32M$60.77M$56.24M$48.99M$58.15M$48.40M$45.48M$31.84M$48.60M$41.60M$43.41M$28.94M$30.30M$37.99M$33.99M$26.31M$32.72M$27.88M$29.41M
Low Forecast$54.96M$67.46M$60.69M$55.67M$50.81M$62.52M$55.62M$51.47M$46.00M$57.77M$48.06M$45.48M$21.22M$48.21M$41.18M$39.73M$19.29M$20.20M$37.99M$33.99M$17.54M$32.72M$27.88M$19.61M
Surprise %-------------0.92%0.95%1.08%1.78%1.69%0.99%1.08%1.67%1.06%1.08%1.08%

Doximity's average Quarter SG&A projection for Mar 24 is $26.53M, based on 4 Wall Street analysts, with a range of $21.22M to $31.84M. The forecast indicates a -40.51% fall compared to DOCS last annual SG&A of $44.60M (Dec 23).

Doximity EPS Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts6661211109813126548136655511121110
EPS-------------$0.26$0.16$0.15$0.16$0.17$0.14$0.12$0.19$0.30$0.19$0.30
Avg Forecast----$0.27$0.37$0.32$0.29$0.23$0.34$0.26$0.22$0.20$0.24$0.17$0.14$0.17$0.18$0.15$0.10$0.15$0.11$0.09$0.06
High Forecast----$0.30$0.40$0.35$0.32$0.28$0.36$0.26$0.22$0.20$0.25$0.19$0.16$0.19$0.19$0.15$0.10$0.15$0.11$0.09$0.06
Low Forecast----$0.27$0.36$0.31$0.28$0.22$0.33$0.25$0.22$0.20$0.22$0.15$0.14$0.17$0.17$0.15$0.10$0.15$0.11$0.09$0.06
Surprise %-------------1.09%0.95%1.05%0.93%0.97%0.93%1.20%1.29%2.69%2.18%4.71%

According to 4 Wall Street analysts, Doximity's projected average Quarter EPS for Mar 24 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a -22.82% decrease compared to DOCS previous annual EPS of $0.26 (Dec 23).

Doximity Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
AMWLAmerican Well$11.00$148.131246.64%Buy
TXG10x Genomics$14.84$46.00209.97%Hold
DHDefinitive Healthcare$4.93$6.0823.33%Hold
SDGRSchrödinger$24.96$28.3313.50%Buy
TDOCTeladoc Health$10.35$11.006.28%Buy
GEHCGE HealthCare$87.85$92.004.72%Buy
CERTCertara$13.89$14.504.39%Buy
ACCDAccolade$6.88$7.032.18%Hold
VEEVVeeva Systems$232.30$236.141.65%Buy
HQYHealthEquity$108.80$107.50-1.19%Buy
DOCSDoximity$57.67$53.00-8.10%Buy
PGNYProgyny$23.25$20.00-13.98%Hold

DOCS Forecast FAQ

Is Doximity a good buy?

Yes, according to 10 Wall Street analysts, Doximity (DOCS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 60.00% of DOCS's total ratings.

What is DOCS's price target?

Doximity (DOCS) average price target is $53 with a range of $43 to $65, implying a -8.10% from its last price of $57.67. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Doximity stock go up soon?

According to Wall Street analysts' prediction for DOCS stock, the company can go down by -8.10% (from the last price of $57.67 to the average price target of $53), up by 12.71% based on the highest stock price target, and down by -25.44% based on the lowest stock price target.

Can Doximity stock reach $90?

DOCS's average twelve months analyst stock price target of $53 does not support the claim that Doximity can reach $90 in the near future.

What is Doximity's current price target trend?

2 Wall Street analysts forecast a $54 price target for Doximity (DOCS) this month, down -6.36% from its last price of $57.67. Compared to the last 3 and 12 months, the average price target decreased by -2.65% and decreased by -22.07%, respectively.

What are Doximity's analysts' financial forecasts?

Doximity's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $593.59M (high $634.91M, low $581.06M), average EBITDA is $183.76M (high $196.55M, low $179.88M), average net income is $251.19M (high $273.92M, low $244.3M), average SG&A $225.17M (high $240.84M, low $220.41M), and average EPS is $1.25 (high $1.37, low $1.22). DOCS's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $643.07M (high $687.84M, low $629.49M), average EBITDA is $199.07M (high $212.93M, low $194.87M), average net income is $0 (high $0, low $0), average SG&A $243.94M (high $260.92M, low $238.79M), and average EPS is $0 (high $0, low $0).

Did the DOCS's actual financial results beat the analysts' financial forecasts?

Based on Doximity's last annual report (Mar 2023), the company's revenue was $419.05M, beating the average analysts forecast of $411.14M by 1.92%. Apple's EBITDA was $135.39M, beating the average prediction of $104.18M by 29.96%. The company's net income was $112.82M, missing the average estimation of $114.58M by -1.53%. Apple's SG&A was $160.27M, beating the average forecast of $121.35M by 32.07%. Lastly, the company's EPS was $0.58, missing the average prediction of $0.599 by -3.13%. In terms of the last quarterly report (Dec 2023), Doximity's revenue was $135.28M, beating the average analysts' forecast of $127.5M by 6.11%. The company's EBITDA was $58.55M, beating the average prediction of $39.47M by 48.35%. Doximity's net income was $47.96M, beating the average estimation of $47.76M by 0.40%. The company's SG&A was $44.6M, missing the average forecast of $48.36M by -7.79%. Lastly, the company's EPS was $0.26, beating the average prediction of $0.238 by 9.09%